US 10,376,476 B2
Panicein compounds, compositions and uses thereof
Isabelle Mus-Veteau, Valbonne (FR); Olivier Thomas, Galway (IE); Marie-Aude Tribalat, Les Arcs (FR); and Stephane Azoulay, Nice (FR)
Assigned to UNIVERSITE NICE SOPHIA ANTIPOLIS, Nice (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR)
Filed by CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and UNIVERSITE NICE SOPHIA ANTIPOLIS, Nice (FR)
Filed on Mar. 14, 2018, as Appl. No. 15/920,486.
Application 15/920,486 is a division of application No. 15/522,300, abandoned, previously published as PCT/EP2015/074771, filed on Oct. 26, 2015.
Claims priority of application No. 14306710 (EP), filed on Oct. 27, 2014.
Prior Publication US 2018/0200200 A1, Jul. 19, 2018
Int. Cl. A61K 31/05 (2006.01); A61K 31/11 (2006.01); A61K 31/353 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 31/11 (2013.01); A61K 31/353 (2013.01)] 14 Claims
 
1. A method for treating a cancer, for reducing cancer metastasis and/or cancer recurrence in a subject comprising a step of administering to a subject a panicein compound in combination with at least one chemotherapeutic drug, wherein the cancer comprises cancer cells expressing the Patched receptor, and wherein the panicein compound is of formula (I)

OG Complex Work Unit Drawing
wherein:
R1 is H, C1-C6 alkyl, C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, C1-C6 halogenoalkyl or —OR4,
R2 is H or C1-C6 alkyl,
R3 is C1-C6 alkyl, —CH2OR4, —C(═O)R4, —C(═O)OR4, —C(═O)NHR4, or —CH2NHR4,
each R4 is independently —H, or C1-C6 alkyl,
R is:

OG Complex Work Unit Drawing
wherein:
bonds (1) and (2) are independently of each other a single bond or a double bond and bonds (1) and (2) are not simultaneously double bonds,
R5 is present when bond (1) is a single bond, and represents —H, or —OR6, and
when present, each R6 is independently H or a C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and
wherein cancer is selected from a melanoma, a breast cancer, a thyroid cancer, a prostate cancer, an esophagus cancer, a gastric cancer, an ovarian cancer, a pancreatic cancer, a glioma, an adrenocortical carcinoma, a leukemia, a multiple myeloma or a sarcoma; and
wherein the at least one chemotherapeutic drug is selected from cisplatin, docetaxel, doxorubicin, methotrexate, temozolomide, 5-fluorouracil (5-FU), dacarbazine and vemurafenib.